Exercise of Options and Total Voting Rights | Company Announcement | Investegate
Source: investegate.co.uk
Brighton, United Kingdom - 24 May 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, announces that it has issued and allotted 200,000 new ordinary shares of